Information  X 
Enter a valid email address

Company Name matching 'Prothena Corporation plc'

Date
Time Source
Company
Announcement
10 Jun 2021 7:18 pm GNW   Prothena Corporation plc Prothena to Participate in JMP Securities Life Sciences Conference on June 16
20 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
11 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
10 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
07 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 May 2021 9:05 pm GNW   Prothena Corporation plc Prothena to Report First Quarter 2021 Financial Results on May 11th
18 Apr 2021 8:05 pm GNW   Prothena Corporation plc Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
15 Apr 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021
07 Apr 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2021 9:05 pm GNW   Prothena Corporation plc Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
24 Mar 2021 12:00 pm GNW   Prothena Corporation plc Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares
23 Mar 2021 8:29 pm GNW   Prothena Corporation plc Prothena Announces Proposed Offering of Ordinary Shares
08 Mar 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
24 Feb 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
11 Feb 2021 1:00 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
05 Feb 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Feb 2021 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
01 Feb 2021 9:15 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
09 Dec 2020 1:00 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
04 Dec 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Nov 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
  1:30 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
28 Oct 2020 8:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Third Quarter 2020 Financial Results on November 4
20 Oct 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
02 Oct 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15 Sep 2020 1:30 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
11 Sep 2020 1:30 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
08 Sep 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
03 Sep 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders
02 Sep 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Aug 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update
05 Aug 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
30 Jul 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Second Quarter 2020 Financial Results on August 6
27 May 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3
06 May 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance
29 Apr 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report First Quarter 2020 Financial Results on May 6
24 Apr 2020 9:30 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19
22 Apr 2020 2:15 pm GNW Factsheet Prothena Corporation plc (0Y3M) Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease
03 Apr 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
31 Mar 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD
03 Mar 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Appointment of Brandon Smith as Chief Business Officer
12 Feb 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
05 Feb 2020 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12
05 Dec 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Appointment of Oleg Nodelman to its Board of Directors
05 Nov 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update
29 Oct 2019 8:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Third Quarter 2019 Financial Results on November 5
06 Aug 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
30 Jul 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Second Quarter 2019 Financial Results on August 6
01 Jul 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Announces Appointment of Paula K. Cobb to its Board of Directors
30 May 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Participate in the Jefferies Healthcare Conference
07 May 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
30 Apr 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report First Quarter 2019 Financial Results on May 7
18 Apr 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
05 Mar 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Participate in Upcoming March Healthcare Conferences
14 Feb 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update
04 Feb 2019 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14
06 Nov 2018 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update
30 Oct 2018 8:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Third Quarter 2018 Financial Results on November 6
07 Aug 2018 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update
31 Jul 2018 9:05 pm GNW Factsheet Prothena Corporation plc (0Y3M) Prothena to Report Second Quarter 2018 Financial Results on August 7


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t